
Opinion|Videos|April 22, 2025
The Role of Prescription Digital Therapeutics in the Schizophrenia Treatment Landscape
Author(s)Gustavo Alva, MD, DFAPA
Gus Alva, MD, discusses how he will be examining notable challenges in schizophrenia care, including access issues, and exploring the potential role of prescription digital therapeutics in addressing these gaps.
Advertisement
Episodes in this series

Now Playing
Summary for Physicians: Introduction to Prescription Digital Therapeutics in Schizophrenia Care
Presenter: Gus Alva, MD
Series Overview: This PsychView video series from Psychiatric Times examines prescription digital therapeutics (PDTs) as part of a multimodal treatment approach for schizophrenia.
Future Episodes: The series will feature discussions focusing on:
- How PDTs can address gaps in provider care
- The ways PDTs can help patients become active stakeholders in their treatment
- Potential solutions to challenges in schizophrenia care, including access issues
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Psychiatric Times
1
Experience With Xanomeline/Trospium in an Acute Inpatient Setting Treating Individuals With Schizophrenia
2
Home-Based tDCS for Depression: Expanding Access to Neuromodulation Treatment
3
FDA Approves Tauklarify (MK-6240) For Tau Pathology Detection in Alzheimer Disease
4
HLP003, Deuterated Psilocin, as an Adjunctive Therapy for Major Depressive Disorder
5







